A Companion Solution for GLP-1 Agonist!, MyoGastro™

Rising Demand for GLP-1 Support GLP-1 medications are experiencing rapid global adoption as effective solutions for weight management and metabolic health, with millions of consumers worldwide embracing these therapies. However, according to the 2025 Kaiser Family Foundation Health Tracking Poll, side effects are the second most common reason why GLP-1 users discontinue treatment. Many patients experience side effects including nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain, and muscle loss. As the use of GLP-1 therapies continues to grow, supportive solutions that help manage these side effects are becoming increasingly important. Myogastro™ Targets GLP-1 Challenges MyoGastro™ is a companion solution for GLP-1 agonists that combines dual probiotics—Vigiis® 101-LAB and XtraMyo™—to help address two of the most common side effects: digestive discomfort and muscle loss. Vigiis® 101-LAB helps relieve GI discomfort and protect the GI tract in GLP-1 users. Derived from Lacticaseibacillus paracasei NTU 101, it supports gut motility and beneficial microbiota to reduce constipation, diarrhea, and abdominal pain, while protecting gastric mucosa from damage caused by nausea and vomiting. XtraMyo™ supports muscle mass and energy in GLP-1 users. Derived from Levilactobacillus brevis SWP-TKLB01, it enhances muscle energy by increasing glycogen storage and mitochondrial SDH activity for ATP production, reducing fatigue and maintaining muscle.